AU753804B2 - Veterinary vaccines - Google Patents

Veterinary vaccines Download PDF

Info

Publication number
AU753804B2
AU753804B2 AU96161/98A AU9616198A AU753804B2 AU 753804 B2 AU753804 B2 AU 753804B2 AU 96161/98 A AU96161/98 A AU 96161/98A AU 9616198 A AU9616198 A AU 9616198A AU 753804 B2 AU753804 B2 AU 753804B2
Authority
AU
Australia
Prior art keywords
clostridium
vaccine composition
vaccine
toxoid
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU96161/98A
Other languages
English (en)
Other versions
AU9616198A (en
Inventor
Richard Buchta
Philip Ralph Lehrbach
Christopher Leigh Schwartzkoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Fort Dodge Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722035.4A external-priority patent/GB9722035D0/en
Application filed by Fort Dodge Australia Pty Ltd filed Critical Fort Dodge Australia Pty Ltd
Publication of AU9616198A publication Critical patent/AU9616198A/en
Application granted granted Critical
Publication of AU753804B2 publication Critical patent/AU753804B2/en
Assigned to WYETH reassignment WYETH Alteration of Name(s) in Register under S187 Assignors: FORT DODGE AUSTRALIA PTY LIMITED
Assigned to ZOETIS W LLC reassignment ZOETIS W LLC Request to Amend Deed and Register Assignors: WYETH
Assigned to ZOETIS SERVICES LLC reassignment ZOETIS SERVICES LLC Request to Amend Deed and Register Assignors: ZOETIS W LLC
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU96161/98A 1997-10-17 1998-10-16 Veterinary vaccines Expired AU753804B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9722035 1997-10-17
GBGB9722035.4A GB9722035D0 (en) 1997-10-17 1997-10-17 Veterinary vaccines
PCT/AU1998/000865 WO1999020305A1 (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Publications (2)

Publication Number Publication Date
AU9616198A AU9616198A (en) 1999-05-10
AU753804B2 true AU753804B2 (en) 2002-10-31

Family

ID=25641911

Family Applications (1)

Application Number Title Priority Date Filing Date
AU96161/98A Expired AU753804B2 (en) 1997-10-17 1998-10-16 Veterinary vaccines

Country Status (5)

Country Link
EP (1) EP1023083A4 (fr)
AU (1) AU753804B2 (fr)
CA (1) CA2307000C (fr)
NZ (1) NZ503636A (fr)
WO (1) WO1999020305A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
GB2448440B (en) * 2005-12-15 2011-05-04 Hancroft Pty Ltd A method for preventing reduced feed intake in animals and treatment of disease conditions
FR2903602B1 (fr) * 2006-07-12 2012-10-26 Seppic Sa Formulation injectable a liberation prolongee de principes actifs, procede pour sa preparation
FR2922767B1 (fr) 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
CN106177935A (zh) * 2016-08-19 2016-12-07 齐鲁动物保健品有限公司 一种反刍动物梭菌病四联灭活疫苗及其制备方法
GB201718251D0 (en) * 2017-11-03 2017-12-20 Univ Sydney Vaccine Compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128325A (en) * 1964-11-11 1968-09-25 Wellcome Found Improvements in water-in-oil emulsion vaccines
AU5961090A (en) * 1989-07-03 1991-01-17 Societe D'exploitation De Produits Pour Les Industries Chimiques - Seppic Injectable multi-phase emulsions
WO1998027964A1 (fr) * 1996-12-24 1998-07-02 Fort Dodge Australia Pty. Limited Vaccins a usage veterinaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843451A (en) * 1970-08-20 1974-10-22 Burroughs Wellcome Co Microorganism production
FR2717694B1 (fr) * 1994-03-22 1996-05-03 Seppic Sa Une composition comprenant un plasmide recombinant et ses utilisations comme vaccin et médicament.
TW410158B (en) * 1995-11-30 2000-11-01 Chemo Sero Therapeut Res Inst Oil adjuvant vaccine and method for preparing same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128325A (en) * 1964-11-11 1968-09-25 Wellcome Found Improvements in water-in-oil emulsion vaccines
AU5961090A (en) * 1989-07-03 1991-01-17 Societe D'exploitation De Produits Pour Les Industries Chimiques - Seppic Injectable multi-phase emulsions
WO1998027964A1 (fr) * 1996-12-24 1998-07-02 Fort Dodge Australia Pty. Limited Vaccins a usage veterinaire

Also Published As

Publication number Publication date
EP1023083A1 (fr) 2000-08-02
WO1999020305A1 (fr) 1999-04-29
EP1023083A4 (fr) 2006-06-14
AU9616198A (en) 1999-05-10
WO1999020305A8 (fr) 1999-07-08
CA2307000C (fr) 2011-01-04
CA2307000A1 (fr) 1999-04-29
NZ503636A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
Byars et al. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity
EP1613346B1 (fr) Emulsions microfluidifiees d'huile dans l'eau et compositions de vaccins
EP1333858B1 (fr) Vaccins a reponse immunitaire accrue et leurs procedes de preparation
AU709104B2 (en) Vaccine adjuvants
US5376369A (en) Vaccine adjuvant
AU712972B2 (en) Adjuvants for viral vaccines
EP1051189A2 (fr) Formulations de vaccin
AU753804B2 (en) Veterinary vaccines
AU626271B2 (en) Vaccine adjuvant
US3920811A (en) Adjuvant compositions
Pratanaphon et al. Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia)
US6524592B2 (en) Veterinary vaccines
Tengerdy et al. Vitamin E adjuvant formulations in mice
Harrison et al. Duration of immunity, efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated with saponin or selected adjuvants
Edelman An overview of adjuvant use
CA2487968C (fr) Nouveau regime posologique de medicaments
AU744308B2 (en) Antigen vectors in the form of multilamellar vesicles
Brey Development of vaccines based on formulations containing nonionic block copolymers
AU776364B2 (en) Veterinary vaccines
WO1998027964A1 (fr) Vaccins a usage veterinaire
Nauciel Delayed hypersensitivity to azobenzenearsonate amino acids conjugates. In vitro study of the specificity of the immune response by 3H-thymidine incorporation into lymph node cells
Wardlaw et al. Loss of adjuvanticity in rats for the hyperacute form of allergic encephalomyelitis and for reaginic antibody production in mice of a phenotypic variant of Bordetella pertussis.
JP3270473B2 (ja) パスツレラ・マルトサイダ・トキソイドワクチン
JPH11106351A (ja) オイルアジュバントワクチンおよびその製造方法
Stewart-Tull The future potential for the use of adjuvants in human vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: WYETH

Free format text: FORMER OWNER WAS: FORT DODGE AUSTRALIA PTY. LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired